{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T04:40:22Z","timestamp":1784954422028,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.urolonc.2019.10.014","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T22:57:43Z","timestamp":1576709863000},"page":"76.e11-76.e17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Prognostic significance of the controlling nutritional status (CONUT) score in advanced urothelial carcinoma patients"],"prefix":"10.1016","volume":"38","author":[{"given":"Hiroaki","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasukazu","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madoka","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Tobisu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2019.10.014_bib0001","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0002","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","article-title":"Randomized phase III study comparing Paclitaxel\/Cisplatin\/ Gemcitabine and Gemcitabine\/Cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987","volume":"30","author":"Bellmunt","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0003","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0004","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","article-title":"Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy","volume":"17","author":"Bajorin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0005","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1002\/cncr.28146","article-title":"Nomogram for predicting survival in patients with unresectable and\/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy","volume":"119","author":"Galsky","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0006","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/jnci\/djt015","article-title":"Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy","volume":"105","author":"Iasonos","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0007","doi-asserted-by":"crossref","first-page":"83","DOI":"10.21037\/apm.2016.03.02","article-title":"Inter-rater reliability in performance status assessment among health care professionals: a systematic review","volume":"5","author":"Chow","year":"2016","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0008","first-page":"400","article-title":"What is subjective global assessment of nutritional status? 1987. Classical article","volume":"23","author":"Detsky","year":"2008","journal-title":"Nutr Hosp"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0009","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2152\/jmi.62.119","article-title":"Objective Data Assessment (ODA) methods as nutritional assessment tools","volume":"62","author":"Hamada","year":"2015","journal-title":"J Med Invest"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0010","first-page":"38","article-title":"CONUT: a tool for controlling nutritional status. First validation in a hospital population","volume":"20","author":"Ignacio de Ulibarri","year":"2005","journal-title":"Nutr Hosp"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0011","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-016-2696-0","article-title":"The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study","volume":"16","author":"Toyokawa","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132488","article-title":"Impact of the preoperative controlling nutritional status (CONUT) score on the survival after curative surgery for colorectal cancer","volume":"10","author":"Iseki","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0013","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4616-y","article-title":"Preoperative controlling nutritional status (CONUT) score as a predictor of long-term outcome after curative resection followed by adjuvant chemotherapy in stage II-III gastric Cancer","volume":"18","author":"Liu","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0014","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.21037\/jtd.2017.07.108","article-title":"Prognostic impact of controlling nutritional status score in resected lung squamous cell carcinoma","volume":"9","author":"Toyokawa","year":"2017","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0015","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1245\/s10434-018-6672-6","article-title":"Prognostic significance of preoperative controlling nutritional status (CONUT) score in patients undergoing hepatic resection for hepatocellular carcinoma: a multi-institutional study","volume":"25","author":"Harimoto","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0016","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013409","article-title":"Prognostic impact of the controlling nutritional status score following curative nephrectomy for patients with renal cell carcinoma","volume":"97","author":"Zheng","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001216","article-title":"Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration","volume":"9","author":"Altman","year":"2012","journal-title":"PLoS Med"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115895","article-title":"Sarcopenia as a prognostic biomarker of advanced urothelial carcinoma","volume":"10","author":"Fukushima","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0019","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.juro.2015.08.071","article-title":"Prognostic significance of sarcopenia in patients with metastatic renal cell carcinoma","volume":"195","author":"Fukushima","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0020","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1464-410X.2012.11153.x","article-title":"Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin","volume":"110","author":"Saito","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0021","doi-asserted-by":"crossref","first-page":"e637","DOI":"10.1016\/j.clgc.2017.12.009","article-title":"Real-world outcomes in advanced urothelial cancer and the role of neutrophil to lymphocyte ratio","volume":"16","author":"Yip","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0022","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.lfs.2016.11.033","article-title":"TNF-alpha and cancer cachexia: Molecular insights and clinical implications","volume":"170","author":"Patel","year":"2017","journal-title":"Life Sci"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0023","first-page":"845","article-title":"[Association of interleukin-10 gene polymorphism with cachexia in patients with gastric cancer]","volume":"32","author":"Sun","year":"2010","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0024","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/carcin\/bgl250","article-title":"Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer","volume":"28","author":"Zhang","year":"2007","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40425-019-0549-5","article-title":"Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with Cytokines?","volume":"7","author":"Menetrier-Caux","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0026","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1136\/ard.2008.104844","article-title":"Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor","volume":"69","author":"Hashizume","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0027","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11357-018-0022-2","article-title":"Calorie restriction induces reversible lymphopenia and lymphoid organ atrophy due to cell redistribution","volume":"40","author":"Contreras","year":"2018","journal-title":"Geroscience"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0028","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.clnu.2014.03.006","article-title":"Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial","volume":"33","author":"Sanchez-Lara","year":"2014","journal-title":"Clin Nutr"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0029","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1470-2045(14)70155-X","article-title":"MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: an open-label, phase 1 dose-escalation and expansion study","volume":"15","author":"Hong","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0030","doi-asserted-by":"crossref","first-page":"7631","DOI":"10.1200\/jco.2010.28.15_suppl.7631","article-title":"ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled trial","volume":"28","author":"Schuster","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0031","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11912-016-0522-0","article-title":"Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER Trials)","volume":"18","author":"Crawford","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0032","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2217\/fon.14.14","article-title":"Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome","volume":"10","author":"Currow","year":"2014","journal-title":"Future Oncol"},{"key":"10.1016\/j.urolonc.2019.10.014_bib0033","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/SPC.0000000000000016","article-title":"Nutritional counseling and nutritional supplements: a cornerstone of multidisciplinary cancer care for cachectic patients","volume":"7","author":"Isenring","year":"2013","journal-title":"Curr Opin Support Palliat Care"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143919304387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143919304387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:18:13Z","timestamp":1761041893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143919304387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1078143919304387"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2019.10.014","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic significance of the controlling nutritional status (CONUT) score in advanced urothelial carcinoma patients","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2019.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}